cbdMD, Inc. Stock

YCBD

US12482W4087

Pharmaceuticals

Market Closed - NYSE Other stock markets 23:00:00 09/07/2026 +03			5-day change	1st Jan Change
0.8100 ^USD	+8.00%		+19.14%	-40.00%

07-07	Cbdmd Completes Self-Affirmed Gras Determination for Broad Spectrum Cbd	CI
07-01	CbdMD Launches Oasis Mixer, A Hemp-Derived Zero-Proof THC Spirit	CI

Last Transcript: cbdMD, Inc.

CbdMD, Inc., Q2 2026 Earnings Call, May 14, 2026

05-15

More transcripts

Analysts' recommendations: cbdMD, Inc.

05/10/23	Maxim Starts Coverage on cbdMD with Buy Rating, $3 Price Target	MT
18/06/21	CBDMD : Cantor Fitzgerald Adjusts Price Target for cbdMD to $3.25 from $4.10, Maintains Neutral Rating	MT

More recommendations

Managers and Directors: cbdMD, Inc.

Manager	Title	Age	Since
T. Kennedy CEO	Chief Executive Officer	47	01/03/2023
Zeb Booker CTO	Chief Tech/Sci/R&D Officer	-	01/01/2019
Sibyl Swift CTO	Chief Tech/Sci/R&D Officer	45	-

Director	Title	Age	Since
Jeffrey Porter BRD	Director/Board Member	66	10/04/2025
T. Kennedy BRD	Director/Board Member	47	18/12/2024
Bakari Sellers BRD	Director/Board Member	41	01/03/2017

More insiders

cbdMD, Inc. is a consumer wellness company focused on the development, manufacturing, marketing, and sale of supplement brands powered by natural compounds. Its hemp-derived cannabinoids, include full-spectrum cannabidiol (CBD) formulations, hemp-derived Delta-9 THC products and a range of functional products designed to address key wellness needs, such as sleep, recovery, mood, discomfort, mobility, cognitive function, and stress management. It operates a multi-brand portfolio anchored by its flagship cbdMD line, which offers oils, gummies, capsules, soft-gels, topicals, functional formulations, and hemp-derived compliant Delta-9 THC products. Its Paw CBD pet-wellness brand provides tinctures, chews, and topicals for dogs and cats. Its ATRX platform offers non-cannabinoid functional ingredients such as functional mushrooms. Its Herbal Oasis (Oasis) brand is a premium hemp-derived THC-infused social seltzer that blends cannabinoids and nootropic mushrooms.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
09/07/26	$0.8100	+8.00%	245,745
08/07/26	$0.7500	+1.64%	261,863
07/07/26	$0.7379	+3.64%	254,015
06/07/26	$0.7120	+3.94%	87,118
02/07/26	$0.6850	+0.75%	72,420

Delayed Quote NYSE

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.7500USD

Average target price

2.000USD

Spread / Average Target

+166.67%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Cap	7.87M 6.89M 6.35M 5.87M 11.16M 751M 11.34M 76.06M 29.78M 370M 29.56M 28.92M 1.28B	P/E 2026 *	-4.26x	P/E 2027 *	-11.6x
Enterprise Value	7.87M 6.89M 6.35M 5.87M 11.16M 751M 11.34M 76.06M 29.78M 370M 29.56M 28.92M 1.28B	EV / Sales 2026 *	0.36x	EV / Sales 2027 *	0.34x
Free-Float	89.32%	Yield 2026 *	-	Yield 2027 *	-

07-07	Cbdmd Completes Self-Affirmed Gras Determination for Broad Spectrum Cbd	CI
07-01	CbdMD Launches Oasis Mixer, A Hemp-Derived Zero-Proof THC Spirit	CI
06-16	CbdMD, Inc. Appoints Wade Brown as Chief Marketing Officer	CI
05-15	CbdMD, Inc., Q2 2026 Earnings Call, May 14, 2026
05-15	CbdMD reports 19% year-over-year and 12% sequential revenue growth	RE
05-14	CbdMD, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2026	CI
04-06	Hawkeye Systems, Inc. Announces President and Directorate Appointments	CI
04-01	CbdMD, Inc. Announces Launch of Clinical Healthcare Channel to Support First Federal Pathway for Hemp-Derived CBD in Medicare	CI
02-18	CbdMD, Inc., Q1 2026 Earnings Call, Feb 17, 2026
02-18	CbdMD, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2025	CI
02-03	Cbdmd, Inc.'S Herbal Oasis Expands into Louisiana with Morales Beverage Group Following Strong Texas Momentum	CI
01-29	CbdMD, Inc. Strengthens Regulatory Science Platform to Support Emerging Regulatory Cannabinoid Evaluation Pathways	CI
01-14	cbdMD announces strategic acquisition of Bluebird Botanicals	RE

07-09	CbdMD's Bluebird Botanicals Announces Official Partnership With Denver Audubon to Support Bird Conservation	PR
07-07	CbdMD Sets a New Safety Standard for Broad Spectrum CBD With Self-Affirmed GRAS Determination	PR
07-01	Oasis Launches Hemp-Derived Mixer	PR
06-25	CbdMD Welcomes White House Call for Fair Treatment of Hemp-Derived Products	PR
06-16	CbdMD Appoints Wade Brown Chief Marketing Officer	PR

1 day	+8.00%
1 week	+19.14%
Current month	+20.36%
1 month	+12.50%
3 months	+15.71%
6 months	-25.00%
Current year	-40.00%

1 week	0.68	0.82
1 month	0.65	0.82
Current year	0.63	1.34
1 year	0.47	2.56
3 years	0.47	13.84
5 years	0.47	1,051.78
10 years	0.47	2,606.4

cbdMD, Inc. Stock

Stocks

YCBD

US12482W4087

Pharmaceuticals

Valuation: cbdMD, Inc.

Chart: cbdMD, Inc.

Latest news : cbdMD, Inc.

Last Transcript: cbdMD, Inc.

Analysts' recommendations: cbdMD, Inc.

Press Releases: cbdMD, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: cbdMD, Inc.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

Date	Insider	Type	Main position	Quantity	% Market Cap.
04-14	Bakari Sellers	Free	Director	1,572	0.0150%
04-14	Jeffrey Porter	Free	Director	1,572	0.0150%
04-14	William Raines	Free	Director	1,572	0.0150%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CBDMD, INC.	+8.00%	+19.14%	-6.25%	-93.11%	7.87M
ELI LILLY AND COMPANY	+0.09%	+2.12%	+56.49%	+169.19%	1,084B
JOHNSON & JOHNSON	-1.63%	+2.02%	+66.31%	+62.70%	634B
ABBVIE INC.	-1.12%	-0.46%	+31.69%	+84.44%	447B
ROCHE HOLDING AG	+0.18%	+2.04%	+30.19%	+26.51%	330B
ASTRAZENECA PLC	-6.22%	-3.61%	+29.15%	+32.09%	295B
NOVARTIS AG	-1.27%	-0.56%	+27.21%	+46.39%	285B
NOVO NORDISK A/S	-0.93%	-1.19%	-28.85%	-40.38%	218B
AMGEN INC.	-1.19%	+0.63%	+22.43%	+66.30%	199B
GILEAD SCIENCES, INC.	-0.72%	+7.04%	+21.41%	+81.19%	169B
Average	-0.14%	+3.30%	+24.98%	+43.53%	365.99B
Weighted average by Cap.	-0.58%	+2.48%	+39.76%	+84.80%

	2026 *	2027 *
Net sales	22.15M 19.38M 17.87M 16.52M 31.39M 2.11B 31.91M 214M 83.8M 1.04B 83.16M 81.36M 3.6B	23.26M 20.35M 18.76M 17.34M 32.96M 2.22B 33.51M 225M 87.99M 1.09B 87.32M 85.43M 3.78B
Net income	-1.9M -1.66M -1.53M -1.42M -2.69M -181M -2.74M -18.38M -7.19M -89.26M -7.14M -6.99M -309M	-902K -789K -728K -673K -1.28M -86.03M -1.3M -8.71M -3.41M -42.33M -3.39M -3.31M -146M
Net Debt	-	-